The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | Proton and photon therapy in managing hematological malignancies
Bouthaina Dabaja, MD from the MD Anderson Cancer Center, Houston, TX provides an overview of her work using proton therapy to reduce the late effects of lymphoma treatment. Dr Dabaja explains how proton therapy has been of instrumental value in reducing toxic radiation. This is important to lymphoma patients, as due to it being a highly curable disease, they will live long enough to see any lasting effects of radiation therapy. She explains some of the limitations of proton therapy and also how it compares to photons in managing hematological malignancies. Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.
